Advanced in Endometrial Stromal Sarcoma

Dr. Shohreh Shahabi

Gynecologic Oncology | Obstetrics and Gynecology
250 E Superior St Ste 4-420, 
Chicago, IL 
Advanced in Endometrial Stromal Sarcoma
250 E Superior St Ste 4-420, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shohreh Shahabi is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Chicago, Illinois. Dr. Shahabi is rated as an Advanced provider by MediFind in the treatment of Endometrial Stromal Sarcoma. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy.

Her clinical research consists of co-authoring 77 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Endometrial Stromal Sarcoma.

Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in CT
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

250 E Superior St Ste 4-420, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer
An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Guadecitabine, Pembrolizumab
Study Phase: Phase 2
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
Enrollment Status: Completed
Publish Date: November 16, 2021
Intervention Type: Procedure, Drug, Other
Study Phase: Early Phase 1
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

77 Total Publications

Leveraging chromatin packing domains to target chemoevasion in vivo.
Leveraging chromatin packing domains to target chemoevasion in vivo.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 22, 2025
Similar Doctors
Distinguished in Endometrial Stromal Sarcoma
Dr. Sudarshan K. Sharma
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Endometrial Stromal Sarcoma
Dr. Sudarshan K. Sharma
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Ahp Specialty Care Nfp

120 N Oak St, 
Hinsdale, IL 
 (17.0 miles away)
630-856-6990
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Sudarshan Sharma is a Gynecologic Oncologist and an Oncologist in Hinsdale, Illinois. Dr. Sharma is rated as a Distinguished provider by MediFind in the treatment of Endometrial Stromal Sarcoma. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Oophorectomy, and Lymphadenectomy. Dr. Sharma is currently accepting new patients.

Distinguished in Endometrial Stromal Sarcoma
Dr. Summer B. Dewdney
Gynecologic Oncology | Obstetrics and Gynecology
Distinguished in Endometrial Stromal Sarcoma
Dr. Summer B. Dewdney
Gynecologic Oncology | Obstetrics and Gynecology

Rush University Medical Group

1653 W Congress Pkwy, 
Chicago, IL 
 (3.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Summer Dewdney is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Chicago, Illinois. Dr. Dewdney is rated as a Distinguished provider by MediFind in the treatment of Endometrial Stromal Sarcoma. Her top areas of expertise are Endometrial Cancer, Cervical Cancer, Endometrial Stromal Sarcoma, Hysterectomy, and Vaginectomy. Dr. Dewdney is currently accepting new patients.

Distinguished in Endometrial Stromal Sarcoma
Dr. Amina M. Ahmed
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Endometrial Stromal Sarcoma
Dr. Amina M. Ahmed
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Rush University Medical Group

1700 W Van Buren St, 
Chicago, IL 
 (3.2 miles away)
312-563-2875
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Amina Ahmed is a Gynecologic Oncologist and an Oncologist in Chicago, Illinois. Dr. Ahmed is rated as a Distinguished provider by MediFind in the treatment of Endometrial Stromal Sarcoma. Her top areas of expertise are Endometrial Stromal Sarcoma, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Ureteroscopy, and Oophorectomy. Dr. Ahmed is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shahabi's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile